A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis




Julkaisun tekijät: Santosh Lamichhane, Alex M Dickens, Partho Sen, Heikki Laurikainen, Faith Borgan, Jaana Suvisaari, Tuulia Hyötyläinen, Oliver Howes, Jarmo Hietala, Matej Orešič

Kustantaja: Oxford academic

Julkaisuvuosi: 2020

Journal: Schizophrenia Bulletin

Lehden akronyymi: Schizophrenia Bulletin

eISSN: 1745-1701

DOI: http://dx.doi.org/10.1093/schbul/sbaa087


Tiivistelmä

Patients with schizophrenia have a lower than average life span, largely due to the increased prevalence of cardiometabolic comorbidities. There is an unmet public health need to identify individuals with psychotic disorders who have a high risk of rapid weight gain and who are at risk of developing metabolic complications. Here, we applied mass spectrometry-based lipidomics in a prospective study comprising 48 healthy controls (CTR), 44 first-episode psychosis (FEP) patients, and 22 individuals at clinical high risk (CHR) for psychosis, from 2 study centers (Turku, Finland and London, UK). Baseline serum samples were analyzed using lipidomics, and body mass index (BMI) was assessed at baseline and after 12 months. We found that baseline triacylglycerols (TGs) with low double-bond counts and carbon numbers were positively associated with the change in BMI at follow-up. In addition, a molecular signature comprised of 2 TGs (TG[48:0] and TG[45:0]) was predictive of weight gain in individuals with a psychotic disorder, with an area under the receiver operating characteristic curve (AUROC) of 0.74 (95% CI: 0.60–0.85). When independently tested in the CHR group, this molecular signature predicted said weight change with AUROC = 0.73 (95% CI: 0.61–0.83). We conclude that molecular lipids may serve as a predictor of weight gain in psychotic disorders in at-risk individuals and may thus provide a useful marker for identifying individuals who are most prone to developing cardiometabolic comorbidities.


Last updated on 2021-24-06 at 08:44